3,4-dihydro-2H-benzo[1,4]oxazine and thiazine derivatives as CETP inhibitors

A method of treating a disease or condition in a mammal, which disease or condition is affected by the modulation of CETP;

• wherein the disease or condition affected by modulation of CETP is selected from the group consisting of atherosclerosis, peripheral vascular disease, dyslipidemia, hyper-LDL-cholesterolemia, hyperbetaliproteinemia, hypoalphalipoproteinemia, familial-hypercholesterolemia, angina, ischemia, cardiac ischemia, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, vascular complications of diabetes, obesity and Metabolic Syndrome;
• and
• which method comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula (I)
• wherein:
• L is a covalent bond or O;
• X is O;
• Q is C6-10 aryl or 5- or 6-membered heteroaryl;
• n is 0 to 3;
• m is 0 to 3;
• R1 is C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10cycloalkyl, 5- or 6-membered heteroaryl, wherein each of C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-10cycloalkyl, 5- or 6-membered heteroaryl may be optionally substituted;
• or R1 is phenyl optionally substituted with 1 or 2 members selected from Ra and Rb, wherein Ra and Rb are independently selected from the group consisting of optionally substituted C1-4 alkyl, halogenated C1-4alkyl, optionally substituted C2-4 alkenyl, optionally substituted C2-4 alkynyl, optionally substituted C1-4 alkoxy, halogenatedC1-4alkoxy, optionally substituted C1-4 alkylthio, halo, cyano, and hydroxy, or
• Ra and Rb together with the carbon atoms of the phenyl ring to which they are attached form an optionally substituted 5- or 6-membered heterocyclyl fused to the phenyl ring;
• each R2 is independently selected from halo, hydroxy, cyano, C1-4 alkoxy, halogenated C1-4alkoxy, C1-4 alkyl, halogenated C1-4alkyl, C2-4 alkenyl, C2-4 alkynyl and —C(O)H;
• each R3 is independently selected from C1-4 alkyl, halogenated C1-4alkyl, C2-4 alkenyl, C2-4alkynyl, C1-4 alkoxy, halo, cyano, and hydroxy;
• R4 is C1-10 alkyl optionally substituted with 1-3 members independently selected from halo, oxo, hydroxy, halogenated C1-4alkyl, C1-4 alkoxy, C3-8 cycloalkyl, CN, tert-butyldimethylsilyloxy, optionally substituted heterocyclyl and —NRcRd, wherein Rc and Rd are independently selected from H, optionally substituted C1-3 alkyl, —C(O)C1-3alkyl, —C(O)O—C1-3 alkyl, and —SO2C1-3alkyl;
• or
• R4 is C1-6alkyl substituted with heteroaryl or phenyl substituted with 1 to 3 members independently selected from halo, hydroxy, C1-3alkyl, halogenated C1-3alkyl, C1-4alkoxy, or halogenated C1-4alkoxy;
• or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt thereof.